Previous 10 |
IceCure Medical Announces First Peer Reviewed Publication for the 3-Year Interim Analysis of the ICE3 Trial on Cryoablation of Low-Risk, Early-Stage Breast Cancer Dr. Richard Fine to present findings at the Mayo Clinc Conference "Breast Cancer Care: Innovation, Disruptive Techno...
News, Short Squeeze, Breakout and More Instantly...
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society PR Newswire Demand for minimally invasive breast cancer treatment was ove...
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment fo...
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes PR Newswire CAESAREA, Israel , July 1, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medic...